A monograph confirms what an API is. It says nothing about the crystal form or particle size you receive, and those two attributes decide how the material behaves once it is formulated.
The monograph in force confirms identity, purity and assay, not the solid form or particle size supplied. Polymorphic form and particle size govern solubility, dissolution rate, stability and manufacturability, so a batch can pass every monograph test and still perform differently in the finished dosage form than the material used in development.
A pharmacopoeial monograph for an active pharmaceutical ingredient controls chemical identity, purity, assay and a defined set of impurities. It very rarely constrains the solid state the material is delivered in. Two batches from two different manufacturers can both pass every test in the monograph while consisting of different crystalline arrangements of the same molecule, or the same arrangement milled to different particle sizes, and the finished dosage form can behave quite differently as a result. Solid form and particle size sit alongside the monograph rather than inside it, and a buyer who checks only assay and impurities against the compendial limits has not checked the two attributes most likely to change how the product performs once it is compressed into a tablet, filled into a capsule or suspended for administration.
A monograph fixes chemical identity, tested by an identification method, purity as measured against a stated impurity profile, an assay range for the active content, and a small number of physical tests such as loss on drying or residue on ignition. It typically does not fix the solid state of the material: which polymorph, solvate, hydrate or amorphous form it takes, nor the particle size distribution the powder is milled to. A handful of monographs for specific molecules do specify a required crystalline form, because the difference is understood to matter enough to control at compendial level, but this is the exception rather than the rule, and a buyer should not assume the monograph has already covered it.
Many organic molecules can crystallise in more than one internal lattice arrangement while remaining chemically identical on a mass spectrum or an infrared trace. Each arrangement is a polymorph, and different polymorphs of the same molecule can differ in melting point, density, mechanical behaviour under compression and, for most buyers the property that matters most, solubility and dissolution rate. A solvate or hydrate incorporates solvent or water molecules directly into the crystal lattice and can behave as a distinct form in every practical sense, including stability and dissolution. An amorphous form has no long range order at all. It usually dissolves faster and appears more soluble than any crystalline form of the same molecule, but it is generally less physically stable and can convert to a crystalline form over time, under mechanical stress, or on exposure to moisture.
For a poorly soluble molecule, dissolution rate can be the step that limits how much of the dose becomes available for absorption, and dissolution rate is exactly the property polymorphic form influences most. A change in form, from the one used when the finished product was developed to a different one supplied later, can move a formulation from adequate to inadequate dissolution without any assay or impurity result changing at all. Even for a molecule that is freely soluble regardless of form, differences in hygroscopicity, chemical stability and compressibility between polymorphs can still affect shelf life and manufacturability.
Particle size distribution shapes dissolution rate through the surface area it presents, content uniformity in a low dose formulation, powder flow during manufacture, and how the material behaves during wet granulation or direct compression. A batch milled to a coarser distribution than the one used in the original development or bioequivalence work can behave like a different substance in the finished dosage form, even when its assay, its impurity profile and its polymorphic form are all identical to the reference batch.
A compliant certificate is not a description of the material. A certificate of analysis that confirms assay and impurities against a monograph says nothing about crystal form or particle size. Two batches can be chemically identical and fully compliant and still be pharmaceutically different materials, and neither fact shows up on the standard specification.
A manufacturer can shift the crystallisation solvent, the cooling rate, the drying conditions or the milling step for reasons that have nothing to do with the chemistry the monograph tests, and any of these can change the polymorphic form or the particle size distribution of what leaves the site. A change of manufacturing site or a change of scale can do the same thing even when the written process description looks unchanged on paper. Storage conditions can matter too: some polymorphic transitions are driven by temperature and humidity cycling during transport or warehousing rather than by anything that happened during manufacture.
Ask for X-ray powder diffraction or differential scanning calorimetry data confirming that the form supplied matches the form used in the product's original development, or the form your own process was validated against. Ask for a particle size specification that states the analytical method, such as laser diffraction, sieve analysis or microscopy, rather than accepting a descriptive term like "micronised" on its own. And put a clause in the quality agreement obliging the manufacturer to notify you before any change to the crystallisation, drying or milling step, since none of those changes will show up in a routine assay result. Where a monograph does specify a required polymorphic form for the molecule you are buying, verify the current requirement for your market and dosage form before relying on a supplier's word for it.
This is the same discipline that applies to reading an impurity profile against a specification: a compliant certificate is a floor, not a description of the material. Active pharmaceutical ingredients sourced without confirmation of solid form and particle size carry a formulation risk that assay and purity testing alone cannot see. Where an independent check of a proposed source is useful, that is the kind of work our sourcing consultancy covers.
NJMC Medical Supplies Co., Ltd is a trading and consultancy company in Nanjing, China, supplying medical equipment, medical consumables and active pharmaceutical ingredients to healthcare institutions, sourced from manufacturers in China and India.
A polymorph is a distinct internal crystal arrangement of the same chemical entity, differing in properties such as solubility, stability and compressibility. A solvate or hydrate incorporates solvent or water molecules into the lattice itself and can behave as its own distinct form. The amorphous form has no long range order, usually dissolves faster than any crystalline form, but is generally less physically stable over time.
Yes. Some transitions are driven by mechanical stress during milling or compression, and others by temperature or humidity cycling during storage and transport. A form that was correct on arrival is not guaranteed to remain the form present when the material is formulated, which is why stability data on the solid state, not only on chemical purity, is worth requesting.
Not necessarily. A monograph rarely fixes polymorphic form or particle size, so two manufacturers can both comply while supplying materially different solid states. Before treating a second source as interchangeable, ask for form and particle size data alongside the usual assay and impurity comparison, and check what your own process was validated against.
Common methods include laser diffraction, sieve analysis and microscopy, each suited to a different size range and material type. A useful specification states the method used alongside the distribution parameters it reports, rather than a single descriptive word such as "micronised", because the method affects the result and the finished product was developed against a specific distribution, not a label.
Send the product or molecule, the grade, the quantity and the destination market. You will get a considered answer about what can be sourced and what documentation comes with it.